It highlights the role of activated NF-κB and downregulated autophagy in regulating AMD cellular phenotypes and suggests that drugs inhibiting NK-κB activation and autophagy downregulation may have the potential to work as anti-AMD therapeutics. The gene discussed is NFKB1; the disease is age-related macular degeneration.